Pl. Zinzani et al., Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience, LEUK LYMPH, 32(5-6), 1999, pp. 571-576
Isolated central nervous system (CNS) relapse was evaluated in terms of inc
idence, risk factors, and outcome in a consecutive cohort of 175 patients w
ith aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or
Burkitt's lymphoma was encountered. All these patients had obtained a compl
ete remission with first-line treatment and none had received prophylactic
CNS treatment at diagnosis. Nine patients (5.2%) developed isolated CNS rel
apse after a median of 8 months from diagnosis. CNS involvement was documen
ted by cerebrospinal fluid (CSF) cytology in 4 patients and on the basis of
radiologic and clinical features in 5 others. Factors significantly associ
ated with a greater likelihood of CNS relapse were advanced stage, B sympto
ms, bone marrow involvement, and high LDH levels in univariate analysis wit
h only advanced stage being of significance in multivariate analysis. All r
elapsed CNS lymphoma patients died within a median time of 4 months from th
e disease recurrence, confirming the poor prognosis after CNS relapse and s
tressing the need to develop new treatment strategies for patients at high
risk of CNS recurrence.